Latest News

August 26, 2015

Request for Proposals: Clinical Trials of Immune Tolerance for Protein/Gene-replacement Therapy

The ITN is currently inviting proposals for novel clinical trials with the aim of inducing tolerance in patients who receive gene/protein-replacement (e.g. hemophilia, Gaucher’s disease) or other exogenous protein therapy, in which the patients are at risk for developing an immune response to the biologic agent. The ideal proposal would have a testable mechanism of tolerance induction and a strategy for assays investigating this mechanism.Full details are included in the RFP.

July 20, 2015

Alefacept Preserves Beta Cell Function in Some New-Onset Type 1 Diabetes Patients Out to Two Years

Individuals with new-onset type 1 diabetes who took two courses of alefacept (Amevive®, Astellas Pharma Inc.) soon after diagnosis show preserved beta cell function after two years compared to those who received a placebo.

February 23, 2015

Early Consumption of Peanuts Prevents Peanut Allergy in High-Risk Infants

The results of the Immune Tolerance Network’s (ITN) “Learning Early About Peanut” (LEAP) study published today in the New England Journal of Medicine demonstrate that consumption of a peanut-containing snack by infants who are at high-risk for developing peanut allergy prevents the subsequent development of allergy.

February 4, 2015

ITN Opens Pilot Study to Compare Allergen Challenge Methods (CAT EEC Study)

On Monday the ITN opened a new pilot study to compare two different methods for assessing allergic responses: environmental exposure chambers and nasal allergen challenges. The CAT EEC study, “Cat Pilot Study – Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC),” is being conducted at Inflamax Research, Inc. in Ontario, Canada and led by Drs.

January 30, 2015

ITN Opens the EXTEND Study in Type 1 Diabetes

A new ITN type 1 diabetes trial opened today at the first site, Sanford Health in Sioux Falls, SD.

January 27, 2015

Request for Proposals: ITN Seeks Antigen-Specific T Cell Tolerance Assays for Myelin-Associated Antigens in Multiple Sclerosis

The ITN has an interest in antigen-specific T cell tolerance in multiple sclerosis, an autoimmune disease in which autoreactive T cells specific for myelin-associated antigens are thought to play a role in pathogenesis. Assessment of antigen-specific tolerance in multiple sclerosis will require reliable assays to detect and phenotype T cell responses to myelin-associated antigens in a clinical trial setting.

January 21, 2015

Immunotherapy Research in Seattle and the ITN

An article in Seattle Magazine about the landscape for immunotherapy in Seattle gives a nice mention of the Benaroya Research Institute and the Immune Tolerance Network:“Immunotherapy is being applied to a multitude of diseases, such as leukemia, melanoma, lupus and Graves’ disease. At the Benaroya Research Institute (BRI) at Virginia Mason, scientists are using immunotherapy to target type 1 diabetes, multiple sclerosis and rheumatoid arthritis. Dr.

January 5, 2015

Stem Cell Transplants May Halt Progression of Multiple Sclerosis

Washington, DC - Three-year outcomes from an ongoing clinical trial suggest that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells may induce sustained remission in some people with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, a progressive autoimmune disease in which the immune system attacks the brain and spinal cord.

November 3, 2014

CALIBRATE Trial for Lupus Nephritis Opens

Last Friday the Immune Tolerance Network (ITN) opened a new combination therapy study in lupus nephritis, CALIBRATE, at University of California, San Francisco (UCSF). The CALIBRATE Study will be led by Drs.

October 29, 2014

Abatacept for Lupus Nephritis (the ACCESS Study)

The results of the ACCESS study, “Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis” sponsored by the Immune Tolerance Network (ITN) and led by Drs.